vs
Side-by-side financial comparison of Royalty Pharma plc (RPRX) and Simpson Manufacturing Co., Inc. (SSD). Click either name above to swap in a different company.
Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $588.0M, roughly 1.1× Simpson Manufacturing Co., Inc.). Royalty Pharma plc runs the higher net margin — 34.4% vs 15.0%, a 19.4% gap on every dollar of revenue. On growth, Simpson Manufacturing Co., Inc. posted the faster year-over-year revenue change (9.1% vs 4.8%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs -0.8%).
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
Simpson Manufacturing Company is a leading building materials manufacturer in the United States that produces structural connectors, fasteners, anchors, and products for new construction and retrofitting.
RPRX vs SSD — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $622.0M | $588.0M |
| Net Profit | $214.2M | $88.2M |
| Gross Margin | — | 45.2% |
| Operating Margin | 62.4% | 19.5% |
| Net Margin | 34.4% | 15.0% |
| Revenue YoY | 4.8% | 9.1% |
| Net Profit YoY | 2.9% | 13.3% |
| EPS (diluted) | $0.49 | $2.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $588.0M | ||
| Q4 25 | $622.0M | $539.3M | ||
| Q3 25 | $609.3M | $623.5M | ||
| Q2 25 | $578.7M | $631.1M | ||
| Q1 25 | $568.2M | $538.9M | ||
| Q4 24 | $593.6M | $517.4M | ||
| Q3 24 | $564.7M | $587.2M | ||
| Q2 24 | $537.3M | $597.0M |
| Q1 26 | — | $88.2M | ||
| Q4 25 | $214.2M | $56.2M | ||
| Q3 25 | $288.2M | $107.4M | ||
| Q2 25 | $30.2M | $103.5M | ||
| Q1 25 | $238.3M | $77.9M | ||
| Q4 24 | $208.2M | $55.4M | ||
| Q3 24 | $544.0M | $93.5M | ||
| Q2 24 | $102.0M | $97.8M |
| Q1 26 | — | 45.2% | ||
| Q4 25 | — | 43.4% | ||
| Q3 25 | — | 46.4% | ||
| Q2 25 | — | 46.7% | ||
| Q1 25 | — | 46.8% | ||
| Q4 24 | — | 44.0% | ||
| Q3 24 | — | 46.8% | ||
| Q2 24 | — | 46.7% |
| Q1 26 | — | 19.5% | ||
| Q4 25 | 62.4% | 13.9% | ||
| Q3 25 | 70.1% | 22.6% | ||
| Q2 25 | 36.3% | 22.2% | ||
| Q1 25 | 94.0% | 19.0% | ||
| Q4 24 | 60.9% | 14.8% | ||
| Q3 24 | — | 21.3% | ||
| Q2 24 | 50.2% | 22.1% |
| Q1 26 | — | 15.0% | ||
| Q4 25 | 34.4% | 10.4% | ||
| Q3 25 | 47.3% | 17.2% | ||
| Q2 25 | 5.2% | 16.4% | ||
| Q1 25 | 41.9% | 14.5% | ||
| Q4 24 | 35.1% | 10.7% | ||
| Q3 24 | 96.3% | 15.9% | ||
| Q2 24 | 19.0% | 16.4% |
| Q1 26 | — | $2.13 | ||
| Q4 25 | $0.49 | $1.34 | ||
| Q3 25 | $0.67 | $2.58 | ||
| Q2 25 | $0.07 | $2.47 | ||
| Q1 25 | $0.55 | $1.85 | ||
| Q4 24 | $0.46 | $1.31 | ||
| Q3 24 | $1.21 | $2.21 | ||
| Q2 24 | $0.23 | $2.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $618.7M | $341.0M |
| Total DebtLower is stronger | $9.0B | — |
| Stockholders' EquityBook value | $9.7B | $2.1B |
| Total Assets | $19.6B | $3.0B |
| Debt / EquityLower = less leverage | 0.92× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $341.0M | ||
| Q4 25 | $618.7M | $384.1M | ||
| Q3 25 | $938.9M | $297.3M | ||
| Q2 25 | $631.9M | $190.4M | ||
| Q1 25 | $1.1B | $150.3M | ||
| Q4 24 | $929.0M | $239.4M | ||
| Q3 24 | $950.1M | $339.4M | ||
| Q2 24 | $1.8B | $354.9M |
| Q1 26 | — | — | ||
| Q4 25 | $9.0B | $300.0M | ||
| Q3 25 | $8.9B | $371.3M | ||
| Q2 25 | $8.0B | $376.9M | ||
| Q1 25 | $7.6B | $382.5M | ||
| Q4 24 | $7.6B | $388.1M | ||
| Q3 24 | $7.6B | $393.8M | ||
| Q2 24 | $7.6B | $399.4M |
| Q1 26 | — | $2.1B | ||
| Q4 25 | $9.7B | $2.0B | ||
| Q3 25 | $9.6B | $2.0B | ||
| Q2 25 | $9.5B | $1.9B | ||
| Q1 25 | $9.8B | $1.9B | ||
| Q4 24 | $10.3B | $1.8B | ||
| Q3 24 | $10.3B | $1.9B | ||
| Q2 24 | $9.8B | $1.8B |
| Q1 26 | — | $3.0B | ||
| Q4 25 | $19.6B | $3.1B | ||
| Q3 25 | $19.3B | $3.0B | ||
| Q2 25 | $18.3B | $3.0B | ||
| Q1 25 | $17.6B | $2.8B | ||
| Q4 24 | $18.2B | $2.7B | ||
| Q3 24 | $18.0B | $2.9B | ||
| Q2 24 | $17.7B | $2.8B |
| Q1 26 | — | — | ||
| Q4 25 | 0.92× | 0.15× | ||
| Q3 25 | 0.93× | 0.19× | ||
| Q2 25 | 0.84× | 0.20× | ||
| Q1 25 | 0.78× | 0.21× | ||
| Q4 24 | 0.74× | 0.21× | ||
| Q3 24 | 0.74× | 0.21× | ||
| Q2 24 | 0.78× | 0.23× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $827.1M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 3.86× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $827.1M | $155.7M | ||
| Q3 25 | $702.6M | $170.2M | ||
| Q2 25 | $364.0M | $125.2M | ||
| Q1 25 | $596.1M | $7.6M | ||
| Q4 24 | $742.5M | $115.8M | ||
| Q3 24 | $703.6M | $103.3M | ||
| Q2 24 | $658.2M | $111.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | $119.0M | ||
| Q3 25 | — | $133.9M | ||
| Q2 25 | — | $87.3M | ||
| Q1 25 | — | $-42.6M | ||
| Q4 24 | — | $60.3M | ||
| Q3 24 | — | $58.1M | ||
| Q2 24 | — | $70.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 22.1% | ||
| Q3 25 | — | 21.5% | ||
| Q2 25 | — | 13.8% | ||
| Q1 25 | — | -7.9% | ||
| Q4 24 | — | 11.7% | ||
| Q3 24 | — | 9.9% | ||
| Q2 24 | — | 11.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | 6.8% | ||
| Q3 25 | — | 5.8% | ||
| Q2 25 | — | 6.0% | ||
| Q1 25 | — | 9.3% | ||
| Q4 24 | — | 10.7% | ||
| Q3 24 | — | 7.7% | ||
| Q2 24 | — | 6.7% |
| Q1 26 | — | — | ||
| Q4 25 | 3.86× | 2.77× | ||
| Q3 25 | 2.44× | 1.58× | ||
| Q2 25 | 12.06× | 1.21× | ||
| Q1 25 | 2.50× | 0.10× | ||
| Q4 24 | 3.57× | 2.09× | ||
| Q3 24 | 1.29× | 1.10× | ||
| Q2 24 | 6.45× | 1.14× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
SSD
Segment breakdown not available.
